FI113969B - Menetelmä CD40:n liukoisen ligandin valmistamiseksi, sitä koodaava nukleiinihappo ja sen käyttö - Google Patents
Menetelmä CD40:n liukoisen ligandin valmistamiseksi, sitä koodaava nukleiinihappo ja sen käyttöInfo
- Publication number
- FI113969B FI113969B FI933862A FI933862A FI113969B FI 113969 B FI113969 B FI 113969B FI 933862 A FI933862 A FI 933862A FI 933862 A FI933862 A FI 933862A FI 113969 B FI113969 B FI 113969B
- Authority
- FI
- Finland
- Prior art keywords
- ligand
- preparation
- nucleic acid
- acid sequence
- soluble
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Catalysts (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/940,605 US5540926A (en) | 1992-09-04 | 1992-09-04 | Soluble and its use in B cell stimulation |
Publications (3)
Publication Number | Publication Date |
---|---|
FI933862A0 FI933862A0 (fi) | 1993-09-03 |
FI933862A FI933862A (fi) | 1994-03-05 |
FI113969B true FI113969B (fi) | 2004-07-15 |
Family
ID=25475138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI933862A FI113969B (fi) | 1992-09-04 | 1993-09-03 | Menetelmä CD40:n liukoisen ligandin valmistamiseksi, sitä koodaava nukleiinihappo ja sen käyttö |
Country Status (17)
Country | Link |
---|---|
US (2) | US5540926A (fi) |
EP (1) | EP0585943B1 (fi) |
JP (1) | JP3529815B2 (fi) |
KR (1) | KR100319126B1 (fi) |
AT (1) | ATE163195T1 (fi) |
AU (1) | AU677788B2 (fi) |
CA (1) | CA2105552C (fi) |
DE (1) | DE69316948T2 (fi) |
DK (1) | DK0585943T3 (fi) |
ES (1) | ES2113980T3 (fi) |
FI (1) | FI113969B (fi) |
GR (1) | GR3026100T3 (fi) |
HU (1) | HU215949B (fi) |
IL (1) | IL106896A (fi) |
NO (1) | NO311808B1 (fi) |
NZ (1) | NZ248569A (fi) |
ZA (1) | ZA936491B (fi) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7405270B2 (en) * | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
CA2121798C (en) * | 1991-10-25 | 2007-07-24 | Richard J. Armitage | Novel cytokine |
US5961974A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
US5981724A (en) * | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
EP0679191B1 (en) * | 1993-01-22 | 2003-12-10 | Immunex Corporation | Detection and treatment of mutations in a cd40 ligand gene |
DK0721469T3 (da) | 1993-09-02 | 2000-05-01 | Dartmouth College | Anti-gp39-antistoffer og anvendelse deraf |
US5869049A (en) * | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
US5874085A (en) * | 1993-11-10 | 1999-02-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Vaccine for enhanced production of IgA antibodies |
WO1995014487A1 (en) * | 1993-11-24 | 1995-06-01 | The Australian National University | Treatment of viral disease with cd40l peptide |
US5674492A (en) * | 1993-12-23 | 1997-10-07 | Immunex Corporation | Method of preventing or treating disease characterized by neoplastic cells expressing CD40 |
US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
US5817516A (en) | 1994-04-28 | 1998-10-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods for proliferating and differentiating B cells with high density membrane CD40 ligand |
GB9425060D0 (en) * | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
US5645837A (en) * | 1995-01-17 | 1997-07-08 | Thomas Jefferson University | Peptides that inhibit T cell activation and methods of using the same |
AU2556195A (en) | 1995-03-13 | 1996-10-02 | Regents Of The University Of Michigan, The | CD40 binding compositions and methods of using same |
DK0832229T3 (da) * | 1995-06-07 | 2004-05-03 | Immunex Corp | CD40L-mutein |
ES2202455T3 (es) * | 1995-06-22 | 2004-04-01 | Biogen, Inc. | Cristales de fragmentos del ligando cd40 y su uso. |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
US6132978A (en) * | 1995-12-19 | 2000-10-17 | National Jewish Medical And Research Center | Method to regulate CD40 signaling |
WO1997034634A1 (en) * | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
US6017527A (en) * | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
EP0961824A4 (en) * | 1996-07-10 | 2003-01-29 | Immunex Corp | DENDRITIC CELL ACTIVATION PROCESS |
US7070771B1 (en) | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
PL193966B1 (pl) * | 1997-01-10 | 2007-04-30 | Biogen Idec Ma | Zastosowanie przeciwciał przeciwko CD40L lub pochodnych |
CA2223225A1 (en) | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
US20050031611A1 (en) * | 1998-05-08 | 2005-02-10 | Beth Israel Deaconess Medical Center | Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis |
JP3581660B2 (ja) | 1999-04-30 | 2004-10-27 | ラ ホヤ インスティチュート フォー アラジー アンド イムノロジー | 潜伏ウイルスの再活性化を予防しウイルスの複製を制御するための方法 |
CA2904259C (en) * | 1999-05-07 | 2016-11-15 | Genentech, Inc. | Use of rituximab to treat vasculitis |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
PL201086B1 (pl) * | 1999-07-12 | 2009-03-31 | Genentech Inc | Zastosowanie przeciwciał wiążących się z antygenem CD20 |
AU6934600A (en) * | 1999-08-27 | 2001-03-26 | Board Of Regents, The University Of Texas System | Cd40 ligand and cd40 agonist compositions and methods of use |
US7118751B1 (en) | 1999-10-14 | 2006-10-10 | Trubion Pharmaceuticals, Inc. | DNA vaccines encoding antigen linked to a domain that binds CD40 |
US20030077263A1 (en) * | 1999-10-29 | 2003-04-24 | Immunex Corporation | Method of activating dendritic cells |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
AU2062601A (en) * | 1999-12-06 | 2001-06-12 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Peptides that stabilize protein antigens and enhance presentation to CD8+ T cells |
US20110041190A1 (en) * | 2002-10-31 | 2011-02-17 | Tykocinski Mark L | Novel chimeric proteins |
AU2048501A (en) * | 2000-02-16 | 2001-08-27 | Genentech Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
CN1592645A (zh) * | 2000-09-18 | 2005-03-09 | 拜奥根Idec公司 | 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法 |
US7786257B2 (en) * | 2000-12-18 | 2010-08-31 | University Of Kansas | Signal-1/signal-2 bifunctional peptide inhibitors |
US20020159996A1 (en) * | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20030211107A1 (en) * | 2002-01-31 | 2003-11-13 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
US20070065436A1 (en) * | 2001-01-31 | 2007-03-22 | Biogen Idec Inc. | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
JP2005510208A (ja) * | 2001-08-03 | 2005-04-21 | ジェネンテック・インコーポレーテッド | TACIs及びBR3ポリペプチドとその用途 |
US20030129193A1 (en) * | 2001-09-27 | 2003-07-10 | Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. | Combined methods for tumor vasculature coaguligand treatment |
US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
BR0313033A (pt) * | 2002-07-25 | 2007-07-10 | Genentech Inc | anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica |
NZ568769A (en) * | 2002-10-17 | 2010-04-30 | Genmab As | Human monoclonal antibodies against CD20 |
JP2007524591A (ja) * | 2003-03-19 | 2007-08-30 | アイソジェニス・インコーポレイテッド | 同種拒絶反応の特異的阻害 |
ES2537738T3 (es) * | 2003-06-05 | 2015-06-11 | Genentech, Inc. | Terapia de combinación para trastornos de células B |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
JP5848861B2 (ja) * | 2004-04-20 | 2016-01-27 | ジェンマブ エー/エスGenmab A/S | Cd20に対するヒトモノクローナル抗体 |
US20090053249A1 (en) * | 2004-07-20 | 2009-02-26 | Yan Qi | Specific Inhibition of Autoimmunity and Diseases Associated With Autoantigens |
EP2399936A3 (en) | 2004-07-26 | 2012-02-22 | Biogen Idec MA Inc. | Anti-CD154 antibodies |
WO2006062094A1 (ja) * | 2004-12-07 | 2006-06-15 | Toray Industries, Inc. | 新規癌抗原ペプチド及びその用途 |
US8333970B2 (en) | 2005-05-18 | 2012-12-18 | Novartis Ag | Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease |
AU2006249305B2 (en) * | 2005-05-26 | 2012-10-18 | Genentech, Inc. | Humanized anti-CD40 antibodies and their methods of use |
AU2006318539B2 (en) * | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
ES2599905T3 (es) * | 2007-11-01 | 2017-02-06 | The Board Of Trustees Of The University Of Arkansas | Composiciones y métodos para aumentar las respuestas inmunitarias a Eimeria |
EP2250279B1 (en) * | 2008-02-08 | 2016-04-13 | MedImmune, LLC | Anti-ifnar1 antibodies with reduced fc ligand affinity |
CA2731797A1 (en) * | 2008-07-25 | 2010-01-28 | Theraclone Sciences | Methods and compositions for discovery of target-specific antibodies using antibody repertoire array (ara) |
CA2732574A1 (en) * | 2008-07-28 | 2010-02-04 | Philip Tan | Multi-specific binding proteins targeting b cell disorders |
US8871515B2 (en) | 2008-09-17 | 2014-10-28 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
AU2010301042B2 (en) | 2009-10-01 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
CA2812057A1 (en) | 2010-09-28 | 2012-04-05 | Kahr Medical Ltd. | Compositions and methods for treatment of hematological malignancies |
EP2820125B1 (en) | 2012-03-02 | 2018-05-09 | The Regents of The University of California | Expansion of alloantigen-reactive regulatory t cells |
MX2015010555A (es) | 2013-02-14 | 2015-09-28 | Univ Arkansas | Composiciones y metodos para mejorar las respuestas inmunes ante una infeccion por eimeria o una infeccion limitante por eimeria. |
US20160075766A1 (en) | 2013-05-21 | 2016-03-17 | Roche Diagnostics Operations, Inc. | Method for producing antibodies using ovine b-cells and uses thereof |
GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
ES2944563T3 (es) * | 2014-05-19 | 2023-06-22 | Hoffmann La Roche | Procedimiento para producir anticuerpos usando linfocitos B ovinos y usos de los mismos |
LT3370733T (lt) | 2015-11-02 | 2021-10-25 | Board Of Regents, The University Of Texas System | Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai |
WO2021050789A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989008114A1 (en) * | 1988-02-25 | 1989-09-08 | The General Hospital Corporation | Rapid immunoselection cloning method |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
WO1990012877A1 (en) * | 1989-04-19 | 1990-11-01 | Cetus Corporation | Multifunctional m-csf proteins and genes encoding therefor |
US5227167A (en) * | 1991-06-11 | 1993-07-13 | Alza Corporation | Long-term delivery device including hydrophobic loading dose |
CA2121798C (en) * | 1991-10-25 | 2007-07-24 | Richard J. Armitage | Novel cytokine |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
IL104684A0 (en) * | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
AU5098493A (en) * | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
US5565321A (en) * | 1993-01-22 | 1996-10-15 | Immunex Corporation | Detection of mutations in a CD40 ligand gene |
-
1992
- 1992-09-04 US US07/940,605 patent/US5540926A/en not_active Expired - Lifetime
-
1993
- 1993-09-02 NZ NZ248569A patent/NZ248569A/en not_active IP Right Cessation
- 1993-09-02 ZA ZA936491A patent/ZA936491B/xx unknown
- 1993-09-02 NO NO19933126A patent/NO311808B1/no not_active IP Right Cessation
- 1993-09-03 DE DE69316948T patent/DE69316948T2/de not_active Expired - Lifetime
- 1993-09-03 FI FI933862A patent/FI113969B/fi not_active IP Right Cessation
- 1993-09-03 CA CA002105552A patent/CA2105552C/en not_active Expired - Lifetime
- 1993-09-03 DK DK93114153T patent/DK0585943T3/da active
- 1993-09-03 IL IL10689693A patent/IL106896A/xx not_active IP Right Cessation
- 1993-09-03 ES ES93114153T patent/ES2113980T3/es not_active Expired - Lifetime
- 1993-09-03 AT AT93114153T patent/ATE163195T1/de active
- 1993-09-03 EP EP93114153A patent/EP0585943B1/en not_active Expired - Lifetime
- 1993-09-03 AU AU46120/93A patent/AU677788B2/en not_active Expired
- 1993-09-03 HU HU9302484A patent/HU215949B/hu unknown
- 1993-09-03 KR KR1019930017670A patent/KR100319126B1/ko not_active IP Right Cessation
- 1993-09-06 JP JP24358193A patent/JP3529815B2/ja not_active Expired - Lifetime
-
1996
- 1996-07-30 US US08/690,096 patent/US5945513A/en not_active Expired - Lifetime
-
1998
- 1998-02-12 GR GR980400208T patent/GR3026100T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR100319126B1 (ko) | 2002-05-13 |
AU677788B2 (en) | 1997-05-08 |
IL106896A0 (en) | 1993-12-28 |
AU4612093A (en) | 1994-03-10 |
KR940007179A (ko) | 1994-04-26 |
IL106896A (en) | 2005-12-18 |
EP0585943B1 (en) | 1998-02-11 |
HU9302484D0 (en) | 1993-11-29 |
US5540926A (en) | 1996-07-30 |
NZ248569A (en) | 1995-10-26 |
ATE163195T1 (de) | 1998-02-15 |
NO311808B1 (no) | 2002-01-28 |
NO933126D0 (no) | 1993-09-02 |
DE69316948D1 (de) | 1998-03-19 |
DK0585943T3 (da) | 1998-09-23 |
NO933126L (no) | 1994-03-07 |
US5945513A (en) | 1999-08-31 |
JP3529815B2 (ja) | 2004-05-24 |
CA2105552C (en) | 2009-08-18 |
HUT69977A (en) | 1995-09-28 |
FI933862A (fi) | 1994-03-05 |
HU215949B (hu) | 1999-03-29 |
ES2113980T3 (es) | 1998-05-16 |
GR3026100T3 (en) | 1998-05-29 |
JPH06315383A (ja) | 1994-11-15 |
FI933862A0 (fi) | 1993-09-03 |
EP0585943A3 (en) | 1994-07-06 |
EP0585943A2 (en) | 1994-03-09 |
DE69316948T2 (de) | 1998-10-01 |
CA2105552A1 (en) | 1994-03-05 |
ZA936491B (en) | 1994-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI113969B (fi) | Menetelmä CD40:n liukoisen ligandin valmistamiseksi, sitä koodaava nukleiinihappo ja sen käyttö | |
DE3886413D1 (de) | Wegwerfeinsatz und verfahren zur herstellung von tee. | |
DE3680130D1 (de) | Verfahren zur vireninaktivierung in gamma-globulin durch waermebehandlung. | |
DE3888205D1 (de) | Verfahren zur behandlung von lungenaffektionen und zubereitungen dafür. | |
ATE51225T1 (de) | Verfahren zur herstellung von 2-oxo-1,3dioxolanen. | |
DE3772429D1 (de) | Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten. | |
DE3779930D1 (de) | Zusammensetzungen zur oberflaechenbehandlung, polymere dafuer und verfahren zur oberflaechenbehandlung. | |
GB9209993D0 (en) | Vaccines | |
DE59702308D1 (de) | Verfahren zur Herstellung salzarmer Präparationen von Kondensationsprodukten | |
IL81221A0 (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them | |
DE3668172D1 (de) | Verfahren zur behandlung von aktiviertem siliciumpulver. | |
DE3886213D1 (de) | Verfahren zur Herstellung von Antioxidant-Zubereitungen. | |
DE69007418D1 (de) | Octadienyläther und verfahren zur herstellung von octadienyläthern. | |
DE68909106D1 (de) | Verfahren zur Herstellung von Katalysatorteilchen. | |
DE3782696D1 (de) | Verfahren zur herstellung von verschiedenfarbigen festen puder-zubereitungen. | |
DE3888443D1 (de) | Verfahren zur Herstellung von Dihydrochinacridonen, Chinacridonen und Chinacridonchinonen. | |
EP0647138A4 (en) | POLYPEPTIDES AVAILABLE FROM FASCIOLA SPECIES, AND VACCINE, THERAPY PROCEDURES AND DNA SEQUENCES ENCODING THESE PEPTIDES. | |
DE68903208D1 (de) | Verfahren zur thermischen behandlung von laktoferrin. | |
ATE87977T1 (de) | Herstellung menschlichen somatomedins c. | |
IL83670A0 (en) | Dna coding for antigen protein of rinderpest virus and process for the preparation thereof | |
IT8619078A0 (it) | Procedimento di trattamento speciale per prodotti in sughero. | |
NL300254I1 (nl) | Verzwakte herpesvirussen, herpesvirussen die vreemd DNA omvatten dat codeert voor een aminozuur-sequentie en vaccin dat het bevat. | |
ATE79518T1 (de) | Verfahren zur herstellung von eiweisshydrolysaten, loeslich in einem saeuremilieu und die erhaltenen hydrolysate. | |
ATE91130T1 (de) | Verfahren zur herstellung von peptiden in fester phase. | |
ATE48647T1 (de) | Verfahren zur herstellung von 1-methyl-1,4androstadien-3,17-dion. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB | Publication of examined application | ||
MM | Patent lapsed | ||
MA | Patent expired |